CL2021001554A1 - Métodos para el tratamiento de discinesia en parálisis cerebral. - Google Patents
Métodos para el tratamiento de discinesia en parálisis cerebral.Info
- Publication number
- CL2021001554A1 CL2021001554A1 CL2021001554A CL2021001554A CL2021001554A1 CL 2021001554 A1 CL2021001554 A1 CL 2021001554A1 CL 2021001554 A CL2021001554 A CL 2021001554A CL 2021001554 A CL2021001554 A CL 2021001554A CL 2021001554 A1 CL2021001554 A1 CL 2021001554A1
- Authority
- CL
- Chile
- Prior art keywords
- methods
- dyskinesia
- cerebral palsy
- treatment
- palsy
- Prior art date
Links
- 208000012661 Dyskinesia Diseases 0.000 title abstract 2
- 206010008129 cerebral palsy Diseases 0.000 title abstract 2
- MKJIEFSOBYUXJB-VFJJUKLQSA-N (3r,11br)-3-(2-methylpropyl)-9,10-bis(trideuteriomethoxy)-1,3,4,6,7,11b-hexahydrobenzo[a]quinolizin-2-one Chemical compound C1CN2C[C@@H](CC(C)C)C(=O)C[C@@H]2C2=C1C=C(OC([2H])([2H])[2H])C(OC([2H])([2H])[2H])=C2 MKJIEFSOBYUXJB-VFJJUKLQSA-N 0.000 abstract 1
- 229950005031 deutetrabenazine Drugs 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862779232P | 2018-12-13 | 2018-12-13 | |
| US201962801450P | 2019-02-05 | 2019-02-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2021001554A1 true CL2021001554A1 (es) | 2022-02-11 |
Family
ID=69173404
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2021001554A CL2021001554A1 (es) | 2018-12-13 | 2021-06-11 | Métodos para el tratamiento de discinesia en parálisis cerebral. |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US11324732B2 (enExample) |
| EP (1) | EP3893876A1 (enExample) |
| JP (1) | JP2022519007A (enExample) |
| KR (1) | KR20210114946A (enExample) |
| CN (1) | CN113395966A (enExample) |
| AU (1) | AU2019395250A1 (enExample) |
| BR (1) | BR112021011386A2 (enExample) |
| CA (1) | CA3123393A1 (enExample) |
| CL (1) | CL2021001554A1 (enExample) |
| IL (1) | IL283920A (enExample) |
| MX (1) | MX2021007063A (enExample) |
| SG (1) | SG11202106344SA (enExample) |
| TW (1) | TWI784220B (enExample) |
| WO (1) | WO2020123900A1 (enExample) |
| ZA (1) | ZA202104786B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022519007A (ja) * | 2018-12-13 | 2022-03-18 | オースペックス ファーマシューティカルズ インコーポレイテッド | 脳性麻痺におけるジスキネジアを処置するためのデューテトラベナジン |
| US20240197714A1 (en) * | 2021-04-15 | 2024-06-20 | Neurocrine Biosciences, Inc. | Methods for the administration of certain vmat2 inhibitors |
| JP2024514873A (ja) * | 2021-04-15 | 2024-04-03 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | デューテトラベナジンおよびｃｙｐ２ｄ６阻害剤の併用投与のための方法 |
| WO2024090922A1 (ko) | 2022-10-24 | 2024-05-02 | 주식회사 디자인셀 | 줄기세포 배양액 및 상기로부터 분리된 세포외소포를 유효성분으로 포함하는 뇌신경계 질환의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ591615A (en) * | 2008-09-18 | 2012-07-27 | Auspex Pharmaceuticals Inc | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| AU2015200243B2 (en) * | 2009-06-24 | 2016-09-29 | Egalet Ltd | Controlled release formulations |
| US20120003330A1 (en) * | 2010-06-01 | 2012-01-05 | Auspex Pharmaceuticals, Inc. | Benzoquinolone inhibitors of vmat2 |
| JP6362601B2 (ja) | 2012-09-18 | 2018-07-25 | オースペックス・ファーマシューティカルズ・インコーポレイテッドＡｕｓｐｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 小胞モノアミン輸送体２の重水素化ベンゾキノリン阻害剤の製剤薬物動態 |
| PL3265085T3 (pl) * | 2015-03-06 | 2022-11-07 | Auspex Pharmaceuticals, Inc. | Sposoby leczenia zaburzeń związanych z nieprawidłowymi ruchami mimowolnymi |
| TWI772382B (zh) * | 2017-03-15 | 2022-08-01 | 美商奧斯拜客斯製藥有限公司 | 氘代丁苯那嗪(deutetrabenazine)之類似物、其製備方法及用途 |
| JP2022519007A (ja) * | 2018-12-13 | 2022-03-18 | オースペックス ファーマシューティカルズ インコーポレイテッド | 脳性麻痺におけるジスキネジアを処置するためのデューテトラベナジン |
-
2019
- 2019-12-13 JP JP2021534126A patent/JP2022519007A/ja active Pending
- 2019-12-13 KR KR1020217021438A patent/KR20210114946A/ko not_active Abandoned
- 2019-12-13 TW TW108145866A patent/TWI784220B/zh active
- 2019-12-13 BR BR112021011386-0A patent/BR112021011386A2/pt not_active Application Discontinuation
- 2019-12-13 CN CN201980089635.4A patent/CN113395966A/zh active Pending
- 2019-12-13 WO PCT/US2019/066150 patent/WO2020123900A1/en not_active Ceased
- 2019-12-13 SG SG11202106344SA patent/SG11202106344SA/en unknown
- 2019-12-13 CA CA3123393A patent/CA3123393A1/en active Pending
- 2019-12-13 US US16/713,917 patent/US11324732B2/en not_active Expired - Fee Related
- 2019-12-13 AU AU2019395250A patent/AU2019395250A1/en not_active Abandoned
- 2019-12-13 EP EP19839001.5A patent/EP3893876A1/en not_active Withdrawn
- 2019-12-13 MX MX2021007063A patent/MX2021007063A/es unknown
-
2021
- 2021-06-11 CL CL2021001554A patent/CL2021001554A1/es unknown
- 2021-06-12 IL IL283920A patent/IL283920A/en unknown
- 2021-07-08 ZA ZA2021/04786A patent/ZA202104786B/en unknown
-
2022
- 2022-04-12 US US17/718,441 patent/US20220409597A1/en not_active Abandoned
-
2023
- 2023-06-28 US US18/343,197 patent/US20240082225A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021011386A2 (pt) | 2021-08-31 |
| EP3893876A1 (en) | 2021-10-20 |
| JP2022519007A (ja) | 2022-03-18 |
| US11324732B2 (en) | 2022-05-10 |
| CA3123393A1 (en) | 2020-06-18 |
| ZA202104786B (en) | 2023-12-20 |
| CN113395966A (zh) | 2021-09-14 |
| TWI784220B (zh) | 2022-11-21 |
| KR20210114946A (ko) | 2021-09-24 |
| US20200188371A1 (en) | 2020-06-18 |
| MX2021007063A (es) | 2021-12-10 |
| IL283920A (en) | 2021-07-29 |
| WO2020123900A1 (en) | 2020-06-18 |
| US20220409597A1 (en) | 2022-12-29 |
| SG11202106344SA (en) | 2021-07-29 |
| TW202034917A (zh) | 2020-10-01 |
| US20240082225A1 (en) | 2024-03-14 |
| AU2019395250A1 (en) | 2021-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024000348A (es) | Mavacamten para su uso en el tratamiento de la cardiomiopatia hipertrofica. | |
| CA193736S (en) | Skin massager | |
| CL2019001874A1 (es) | Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos. | |
| IL283325A (en) | Methods for treatment using adoptive cell therapy | |
| CL2017003006A1 (es) | Métodos de acondicionamiento de pacientes para tratamiento con linfocitos t | |
| SV2018005714A (es) | Composiciones y metodos para disminuir la expresion de tau | |
| TWD170518S (zh) | 美容器具 | |
| DK3377637T3 (da) | Sammensætninger til anvendelse i fremgangsmåder til behandling af sår, lidelser og sygdomme i huden | |
| EP3681479A4 (en) | METHOD OF ADMINISTRATION AND TREATMENT | |
| ZA202104786B (en) | Deutetrabenazine for the treatment of dyskinesia in cerebral palsy | |
| MX388722B (es) | Compuestos para tratar el cancer de ovario. | |
| ZA201807438B (en) | Methods of treating ocular conditions | |
| BR112017003552A2 (pt) | ?métodos para tratar caquexia, para tratar saciedade precoce, para aumentar o tempo de sobrevida, para melhorar a qualidade de vida e para aumentar a massa corporal total? | |
| IL270900A (en) | Treatment of cutaneous disorders | |
| MX394475B (es) | Métodos para el tratamiento de las condiciones relacionadas con la inflamación utilizando moduladores antiinflamatorios y metábolicos pluripotentes. | |
| MX2017016346A (es) | Metodos de tratamiento con taselisib. | |
| MX2017014456A (es) | Usos terapeuticos de l-4-cloroquinurenina. | |
| CL2020000362A1 (es) | Nuevos compuestos. | |
| BR112017009358A2 (pt) | imunoterapia específica de peptídeo t terapêutico para uso no tratamento de metástase cerebral de um paciente com hla-2 positivo | |
| EP4069438A4 (en) | SKIN TREATMENT SYSTEM | |
| EA201991488A1 (ru) | Модуляторы калиевых каналов | |
| IL286863A (en) | Personal wearable medical emergency device | |
| MX386393B (es) | Andrografólido para tratar formas progresivas de esclerosis múltiple. | |
| EP4135553C0 (en) | SKIN TREATMENT SYSTEM | |
| AR107460A1 (es) | Gabapentina oftálmica para el tratamiento de las úlceras corneales |